Table 3 Clinical characteristics of the MM patients and their corresponding bolus and continuous infusion dosages of [13C5]-glutamine
Patient # | Age | Sex | M-Spike | Isotype | Glutamine enrichment | Primary cytogenetics | Prior lines of therapy | BMPC% | S-Phase% |
|---|---|---|---|---|---|---|---|---|---|
MM #1 | 72 | F | 1.3 g/dL | IgG kappa | 4.25% | Trisomies | 2 | 20% | 1.6% |
MM #2 | 65 | F | NQ | NS | 2.89% | t(11;14), +1q | 4 | 95% | 23.8% |
MM #3 | 71 | M | 1.5 g/dL | IgG kappa | 5.40% | Trisomies | 3 | 15% | 0.7% |
MM #4 | 71 | M | 0.5 g/dL | IgG kappa | 5.49% | Trisomies, +1q | 1 | 40% | 2.6% |
MM #5 | 76 | F | NQ; kappa FLC, 47.6 mg/dL | Free kappa | 6.61% | Myc sep, +1q, -17p | 2 | 15% | 3.0% |
MM #6 | 58 | F | NQ; lambda FLC, 11 mg/dL | Free lambda | 6.80% | IgH sep, -17p | 3 | 100% | 8.2% |
MM #7a | 53 | M | 1.9 g/dL | IgG kappa | 3.35% | N/A | 5 | 0% | N/A |
MM #8 | 69 | F | NQ; lambda FLC, 51 mg/dL | Free lambda | 6.63% | Trisomies, +1q | 1 | 20% | 4.5% |
MM #9 | 75 | M | Lambda FLC, 40.5 mg/dL | Free lambda | 6.45% | Trisomies | 4 | 20% | 2.0% |
MM #10 | 71 | M | 1.9 g/dL | IgA kappa | 6.27% | t(11;14), +1q, -17p | 3 | 50% | 1.3% |
MM #11 | 71 | M | NQ | NS | 5.99% | t(11;14), -17p | 2 | 1% | N/A |
MM #12a | 61 | M | 1.2 g/dL | IgG kappa | 4.35% | Trisomies | 1 | 5% | 1.0% |